Research programme: modified natural killer cell based therapeutics - Oxford BioMedica/Green Cross Labcell
Latest Information Update: 20 Jun 2016
At a glance
- Originator Green Cross LabCell; Oxford BioMedica
- Developer Oxford BioMedica
- Class Cell therapies
- Mechanism of Action Natural killer cell modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer